Prognostic value of high-sensitive cardiac troponin-T in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention in Erbil cardiac center

Hewa Mohammed Hamad  Ameen; Mohammed Hasan  Alwan

doi:10.56056/amj.2020.122

Authors

Hewa Mohammed Hamad Ameen FICMS (Med), Trainee of KHCMS, Cardiovascular diseases subspecialty, Surgical Specialty Hospital-cardiac center/ Erbil
Mohammed Hasan Alwan Assist. Prof. FICMS (Med), FICMS (Cardiol), Program Director of KHCMS cardiovascular diseases/Erbil

DOI:

https://doi.org/10.56056/amj.2020.122

Keywords:

High-sensitivity cardiac troponin-T, Myocardial infarction, ST-segment elevation

Abstract

Background and objectives: Background and objectives: Patients with ST-segment elevation myocardial infarction have higher rates of major adverse cardiovascular events including deaths, and it is recommended that these patients should undergo primary percutaneous coronary interventions. The objective of this study was to determine correlation of high-sensitivity cardiac troponin-T measured on admission with the mortality and major adverse cardiovascular event.

Methods: In this study, 167 patients with ST-segment elevation myocardial infarction who underwent primary percutaneous coronary interventions were enrolled. The cut-off value of high-sensitivity cardiac troponin-T measured according to the highest Youden’s index was 528 ng/L. According to this cut-off value, we divided the patients into two groups: those with high-sensitivity cardiac troponin-T ? 528 ng/L (33 patients), and those with high-sensitivity cardiac troponin-T < 528 ng/L (134 patient).

Results: The mean age + SD were 57.56 + 11.11 years; the rate of death was 10.8% (n=18) within follow-up period. Incidence of death among patients with higher cardiac troponin-T values (? 528 ng/L) was 27.3%, which was significantly higher than the incidence (6.7%) among those with lower cardiac troponin-T values. After adjusting for the other factors, higher cardiac troponin-T values were associated with higher death rate. Old age and diabetes was found to be significant risk factors for death. While other outcomes and complications were statistically insignificant. Those who suffered cardiovascular death tend to be older, female gender, diabetics, hypertensive, and had diffused coronary arterial disease.

Conclusions: Initial cardiac troponin-T on admission is independently associated with the higher risks for 2-year all-cause mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventions.

Downloads

Download data is not yet available.

References

Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. The Lancet 1997;349:1269-76.

Crea F, Liuzzo G. Pathogenesis of acute coronary syndromes. J Am Coll Cardiol. 2013;61:1-11.

Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56:786-94.

Anderson JL. Goldman-Cecil Medicine. 25th ed: Saunders Elsevier Philadelphia; 2016.

Newby LK, Jesse RL, Babb JD, et al. ACCF 2012 expert consensus document on practical clinical considerations in the interpretation of troponin elevations: a report of the American College of Cardiology Foundation task force on Clinical Expert Consensus Documents. J Am Coll Cardiol. 2012;60:2427-63.

Garg P, Morris P, Fazlanie AL, et al. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med. 2017;12:147-55.

Apple FS, Collinson PO, Biomarkers ITFoCAoC. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58:54- 61.

Apple FS, Sandoval Y, Jaffe AS, Ordonez-Llanos J. Cardiac troponin assays: guide to understanding analytical characteristics and their impact on clinical care. Clin Chem.2017;63:73-81.

Cullen LA, Mills NL, Mahler S, Body R. Early rule-out and rule-in strategies for myocardial infarction. Clin Chem.2017;63:129-39.

Adams 3rd J, Abendschein DR, Jaffe AS. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 1993;88:750-63.

Giannitsis E, Kurz K, Hallermayer K, Jarausch J, Jaffe AS, Katus HA. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem.2010;56:254-61.

Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018;72:2231-64.

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021- 104.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care 2010;33:S62-S9.

Senni M, Tribouilloy, CM, Rodeheffer, RJ, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991.Circulation 1998; 98:2282-9.

Kerensky RA, Wade M, Deedwania P, Boden WE, Pepine CJ. Revisiting the culprit lesion in non–Q-wave myocardial infarction: results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol. 2002;39:1456-63.

Shaikh AH, Siddiqui MS, Hanif B, Malik F, Hasan K, Adhi F. Outcomes of primary percutaneous coronary intervention (PCI) in a tertiary care cardiac cente. J Pak Med Assoc. 2009;59(7):426-9.

Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care. 2004;8(6):508–512.

Ndrepepa G, Kufner S, Hoyos M, et al. High-sensitivity cardiac troponin T and prognosis in patients with ST-segment elevation myocardial infarction. Journal of Cardiology 2018;72:220-6.

Wijnbergen I, Tijssen J, van’t Veer M, Michels R, Pijls NH. Gender differences in long-term outcome after primary percutaneous intervention for ST-segment elevation myocardial infarction. Catheterization and Cardiovascular Interventions 2013;82:379-84.

De Luca G, Suryapranata H, Dambrink J-H, et al. Sex-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty: data from the Zwolle Myocardial Infarction study. Am Heart J. 2004;148:852-6.

Van der Meer MG, Nathoe HM, van der Graaf Y, Doevendans PA, Appelman Y. Worse outcome in women with STEMI: a systematic review of prognostic studies. Eur J Clin Invest. 2015;45:226-35.

Piccolo R, Franzone A, Koskinas KC, et al. Effect of diabetes mellitus on frequency of adverse events in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2016;118:345-52.

van der Schaaf RJ, Henriques JP, Wiersma JJ, et al. Primary percutaneous coronary intervention for patients with acute ST-elevation myocardial infarction with and without diabetes mellitus. Heart 2006;92:117-8.

Velders MA, Wallentin L, Becker RC, et al. Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial. Am Heart J. 2015;169:879-89. e7.

Wang TK, Snow TA, Chen Y, et al. High-sensitivity troponin level pre-catheterization predicts adverse cardiovascular outcomes after primary angioplasty for ST-elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care. 2014;3:118-25.

Bergmann O, Bhardwaj RD, Bernard S, et al. Evidence for cardiomyocyte renewal in humans. Science 2009;324:98-102.

De Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503-12.

Ndrepepa G, Braun S, Mehilli J, et al. Prognostic value of sensitive troponin T in patients with stable and unstable angina and undetectable conventional troponin. AHJ. 2011;161:68-75.

Hallén J, Buser P, Schwitter J, et al. Relation of cardiac troponin I measurements at 24 and 48 hours to magnetic resonance–determined infarct size in patients with ST-elevation myocardial infarction. Am J Cardiol. 2009;104:1472-7.

Burns RJ, Gibbons RJ, Yi Q, et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol. 2002;39:30-6.

Pride YB, Mohanavelu S, Zorkun C, et al. Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (early glycoprotein IIb/IIIa Inhibition in non–ST-segment elevation acute coronary syndrome) angiographic substudy. JACC Cardiovasc Interv. 2012;5:927-35.

Giannitsis E, Müller-Bardorff M, Lehrke S, et al. Admission troponin T level predicts clinical outcomes, TIMI flow, and myocardial tissue per-fusion after primary percutaneous intervention for acute ST-segment elevation myocardial infarction. Circulation 2001;104:630-5.

Khullar N, Ibrahim A, Saunders J, et al. 16 Prognostic value of high-sensitivity cardiac troponin T in patients with ST-segment-eleva- tion myocardial infarction. Heart 2018;104:A13.

Jeong YH, Lee SW, Lee CW, et al. Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction. Clin Cardiol. 2008 Dec;31(12):572-9.

Ndrepepa G, Braun S, Cassese S, et al. Prognostic value of high-sensitivity troponin T after percutaneous coronary intervention in patients with stable coronary artery disease. Revista Española de Cardiología (English Edition). 2016 Aug 1;69(8):746-53.

Boden H, Ahmed TA, Velders MA, et al. Peak and fixed-time high-sensitive troponin for prediction of infarct size, impaired left ventricular function, and adverse outcomes in patients with first ST-segment elevation myocardial infarction receiving percutaneous coronary intervention. Am J Cardiol.. 2013 May 15;111(10):1387-93.

Ferraro S, Corona S, Lavarra F, Panteghini M. Troponin T measured with highly sensitive assay (hsTnT) on admission does not reflect infarct size in ST-elevation myocardial infarction patients receiving primary percutaneous coronary intervention. (CCLM). 2015 Jul 1;53(8):e173-4.